Loading
A phase 1/2 trial of GSK4418959 in colorectal cancer and endometrial cancer, run by GlaxoSmithKline, active and no longer recruiting.
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT06710847 by GlaxoSmithKline, with 14 participants enrolled, started 2024-12-13 and due to reach its primary completion in 2026-06-22. Interventions recorded: GSK4418959 and PD-1 inhibitor.
Shares GSK, Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer and the tag pipeline.
Shares GSK, Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer and the tag pipeline.
Shares Mismatch-repair-deficient endometrial cancer, GSK, Endometrial cancer and the tag pipeline.
Shares GSK, Endometrial cancer and the tag pipeline.
Shares Mismatch-repair-deficient endometrial cancer, Endometrial cancer and the tag pipeline.
Shares GSK, Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Colorectal cancer and the tag pipeline.